. . . . . "2-((Cyclohexylmethylene)hydrazino)adenosine"@en . . . . . . . . . "# Iskandrian AE: A new generation of coronary vasodilators in stress perfusion imaging. Am J Cardiol. 2007 Jun 1;99(11):1619-20. Epub 2007 Apr 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17531594 # Barrett RJ, Lamson MJ, Johnson J, Smith WB: Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. J Nucl Cardiol. 2005 Mar-Apr;12(2):166-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15812370"@en . "Binodenoson"@en . " "@en . . . "For cardiac pharmacologic stress SPECT imaging, which is used to diagnose coronary artery disease."@en . . . . . . . . "Binodenoson is a highly selective adenosine A2A receptor agonist. The adenosine A2A receptor is necessary for increased cardiac blood flow, and specificity to this particular receptor allows binodenoson to deliver, in a single injection, a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion. Cardiac stress tests allow physicians to identify the presence of cardiovascular disease by examining the flow of blood through the heart."@en . . . "investigational"@en . . . . . . "10 ± 4 minutes"@en . "MRE 0470"@en . . "144348-08-3"@en . "Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A_2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion."@en . . . .